Sponsor Dossier
Maxx Pharma
Sponsor Dossier for Maxx Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABEVMY
- Brand: DICLOFENAC
- Brand: FULPHILA
- Brand: HULIO
- Brand: NEPEXTO
- Brand: OGIVRI
- Brand: ONGENTYS
- Brand: SEMGLEE
About
Maxx Pharma is an Australian Private Company with ABN 33 629 622 224, registered in Victoria. The company is active on the Australian Business Register.
Portfolio
Maxx Pharma has 10 brands on the ARTG, of which 8 are indexable and 5 carry a Product Information document. 4 brands are PBS-listed, 5 have a PBAC outcome on record, and 7 have an AusPAR on record. Notable brands include ABEVMY, DICLOFENAC, FULPHILA, HULIO, NEPEXTO, OGIVRI, ONGENTYS, SEMGLEE, VAXELIS, YESINTEK.
Therapeutic focus
— Oncology: 3 brands — Immunology: 3 brands — Endocrinology: 1 brand — Neurology: 1 brand — Pain Management: 1 brand — Infectious Disease: 1 brand
PBS footprint
4 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-07-01, across 5 brands with a PBAC outcome on record. The latest AusPAR is 2023-02-10, across 7 brands with an AusPAR on record.